Please login to the form below
empagliflozin
This page shows the latest empagliflozin news and features for those working in and with pharma, biotech and healthcare.
FDA’s year-end approvals take annual tally to 46
established drugs Johnson &Johnson’s first-to-market blockbuster Invokana (canagliflozin) - which brought in more than $1.2bn last year - fast-gaining rival Jardiance (empagliflozin) from Eli Lilly and Boehringer Ingelheim
Latest news
-
Lilly mulls divestment of its animal health operations
to surging sales of diabetes drugs Trulicity (dulaglutide) and Jardiance (empagliflozin) and a near five-fold increase for psoriasis drug Taltz (ixekizumab).
-
J&J seeks US OK to add CV claim to Invokana label
If the FDA approves the label, Invokana could be able to match rival SGLT2 inhibitor Jardiance (empagliflozin) from Eli Lilly and Boehringer Ingelheim, which had cardiovascular outcomes data added to its
-
Baricitinib delay casts a pall over Lilly's results update
Also entering a competitive sector was Lilly's new psoriasis drug Taltz (ixekizumab), which nevertheless rocketed to almost $140m in the quarter, while diabetes drug Jardiance (empagliflozin) showed signs of benefiting
-
FDA panel backs CV claims for Novo Nordisk's Victoza
Victoza is the second drug to get a recommendation for improving cardiovascular outcomes in type 2 diabetics after Eli Lilly and Boehringer Ingelheim's SGLT-2 inhibitor Jardiance (empagliflozin), which had
-
Trial of J&J's canagliflozin boosts SGLT2 cardiovascular credentials
The finding backs up the landmark EMPA-REG trial of Eli Lilly and Boehringer Ingelheim's Jardiance (empagliflozin), which was reported in 2015 and provides the first hard evidence of an
More from news
Approximately 15 fully matching, plus 61 partially matching documents found.
Latest Intelligence
-
Market dynamics, marketing and analytics
The remaining two SGLT2s are growing faster than the market, with Jardiance (empagliflozin) leading the market in terms of growth.
-
Interview: Christopher Boulton, AstraZeneca
s empagliflozin, but AstraZeneca's strength is the wide range of oral diabetes products it has to offer, says Boulton. “
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Editor – Medical Education Agency – Bucks
-
Salary TBC
-
Scientific Director
-
Great salary and bebefits
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Account Manager – Med Comms – London
-
Salary TBC
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
-
Senior Programme Executive
-
Salary TBC
-
Senior Medical Writer
-
Great salary and bebefits
Subscribe to our email news alerts
Latest intelligence
- Pharma’s isolated islands of innovation
- With service design and technology often failing the patient, why perspective on improving outcomes need to change...
- Uncertainty, austerity and Brexit
- What does it mean for the life science sector?...
- The Holy Grail of HCP Access
- This is the data you need to gain access....
Quick links
Infographics
